$STAA News

Last published 1w ago

1w agoSTAAQ3 2026 Financial Results Call and Webcast - STAAR SURGICAL COEarnings Call TranscriptsGood day, and welcome to the STAR Surgical 3rd Quarter 2026 Results Call and Webcast. During today's presentation, all parties will be in a listen-only mode. Should you need assistance, please signal a conference special
1w agoSTAAQ3 2026 Financial Results Call and Webcast - STAAR SURGICAL COEarnings Call TranscriptsGood day, and welcome to the STAR Surgical 3rd Quarter 2026 Results Call and Webcast. During today's presentation, all parties will be in a listen-only mode. Should you need assistance, please signal a conference special
1w agoSTAASTAAR SURGICAL CO - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
1w agoSTAASTAAR Surgical Appoints Pascal Aeschlimann as Vice President of Asia PacificBusiness WireFormer STAAR Executive and Ophthalmic Entrepreneur Returns to Lead Commercial Business in the Asia Pacific Region, Excluding China Appointment Reflects STAAR’s Strategy to Localize Senior Commercial Leadership in One
2w agoSTAASTAAR Surgical to Participate in Upcoming Investor ConferencesBusiness WireSTAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that Warren Foust, President and Chief
3w agoSTAASTAAR Surgical to Host Third Quarter 2026 Earnings Results Call and Webcast on November 4, 2026Business WireSTAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results and a
1mo agoSTAASTAAR Surgical Names Andrew Pilon as Vice President of Business DevelopmentBusiness WireAccomplished Ophthalmic Industry Executive and Clinician to Help Advance STAAR’s Strategic Partnerships, Innovation Opportunities, and Multi-Product Platform Strategy STAAR Surgical Company ("STAAR" or the
1mo agoSTAASTAAR Surgical Board Approves $50 Million Share Repurchase AuthorizationBusiness WireSTAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors, at a regularly
2mo agoSTAASTAAR Surgical Releases Landmark Global Report Showing Structural Multi-Market Shift Toward Lens-Based Vision CorrectionBusiness WireShows 80% of Consumers Want to be Free of Glasses and Contacts, 58% Want a Reversible Option, and 59% Are Opposed to Laser Correction Safety Concerns and Procedure Fears Outrank Affordability as Primary Barriers to
2mo agoSTAASTAAR Surgical Names Former CEO David Bailey as Chief Commercial OfficerBusiness WireThe architect of STAAR's global refractive transformation returns to lead STAAR's next commercial chapter as EVO ICL outpaces a declining laser refractive market STAAR Surgical Company ("STAAR" or the
3mo agoSTAAQ2 2026 Financial Results Call and Webcast - STAAR SURGICAL COEarnings Call TranscriptsGreetings, and welcome to the STAR Surgical Second Quarter 2026 Results Conference Call and Webcast. During today's presentation, all parties will be in a listen-only mode. Should you need assistance, please signal a con
3mo agoSTAAQ2 2026 Financial Results Call and Webcast - STAAR SURGICAL COEarnings Call TranscriptsGreetings, and welcome to the STAR Surgical Second Quarter 2026 Results Conference Call and Webcast. During today's presentation, all parties will be in a listen-only mode. Should you need assistance, please signal a con
3mo agoSTAASTAAR Surgical Reports Second Quarter 2026 ResultsBusiness WireNet Sales of $93.5 million, up 111% Y/Y Net Income of $8.1 million, with GAAP EPS of $0.16 Adjusted EBITDA1 of $20.0 million, or $0.39 per diluted share Earnings Call and Webcast Today at 5:30 PM Eastern STAAR
3mo agoSTAASTAAR Surgical Appoints Warren Foust as President and Chief Executive OfficerBusiness WireDeborah Andrews appointed Executive Vice President and Chief Financial Officer STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of
3mo agoSTAASTAAR Surgical to Host Second Quarter 2026 Earnings Results Call and Webcast on August 12, 2026Business WireSTAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results in
3mo agoSTAASTAAR Surgical Announces Preliminary Net Sales for Second Quarter 2026Business WireSTAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced strong preliminary net sales for the second
5mo agoSTAASTAAR Surgical Announces Participation in Upcoming Investor ConferencesBusiness WireSTAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that management will participate
6mo agoSTAA1Q 2026 Financial Results Call and Webcast - STAAR SURGICAL COEarnings Call TranscriptsGreetings, and welcome to the STAR Surgical First Quarter 2026 Results Call and Webcast. During today's presentation, all parties will be in a listen-only mode. I would now like to turn the call over to Connie Johnson, D
6mo agoSTAASTAAR Surgical Reports First Quarter 2026 Results; Issues Shareholder LetterBusiness WireNet Sales of $93.5 million, highest first quarter Net Sales in Company's history, up 119.6% Y/Y Net Income of $5.2 million, with GAAP EPS of $0.10 Adjusted EBITDA1 of $24.4 million, or $0.48 per diluted
6mo agoSTAASTAAR Surgical to Host First Quarter 2026 Earnings Results Call and Webcast on May 13, 2026Business WireSTAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial
7mo agoSTAASTAAR Surgical Announces Preliminary Net Sales for First Quarter 2026Business WireSTAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced preliminary net sales for the
8mo agoSTAA4Q 2025 Financial Results Call and Webcast - STAAR SURGICAL COEarnings Call TranscriptsGood day and welcome to the STAR Surgical Company 4th Quarter 2025 Financial Results Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pre
8mo agoSTAASTAAR Surgical Issues Shareholder LetterBusiness WireSTAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued a Shareholder Letter on Tuesday,
8mo agoSTAASTAAR Surgical Reports Fourth Quarter and Fiscal Year 2025 ResultsBusiness WireConfident in China Progress and Future Roadmap A Clear Path Toward Sustainable Profitability and Growth Board and Leadership Transitions Support Strategy Execution and Shareholder Value Creation STAAR Interim
8mo agoSTAASTAAR Surgical Surpasses 4 Million ICLs Sold Globally, Reflecting Ongoing Shift Away from Laser-Based Vision CorrectionBusiness WireSTAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that more than 4 million
8mo agoSTAASTAAR Surgical to Host Fourth Quarter and Fiscal Year 2025 Earnings Conference Call and Webcast on March 3, 2026Business WireSTAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial
8mo agoSTAAFDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision CorrectionBusiness WireNew FDA expansion of U.S. age indication extends EVO ICL use for patients 21 to 60 years old – making EVO ICL available to nearly 8 million additional refractive patients Lens-based vision correction with EVO ICL is
9mo agoSTAASTAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOsBusiness WireSearch Committee Has Initiated a Global Search to Select Next CEO STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer®
10mo agoALC STAAAlcon Terminates Agreement to Acquire STAAR SurgicalBusiness WireAd hoc announcement pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today terminated its definitive merger agreement with STAAR Surgical Company
10mo agoALC STAABroadwood Partners Denounces STAAR Surgical's Fourth Delay of the Shareholder Vote on the Company's Proposed Sale to AlconBusiness WireUrges Board to Allow Shareholders to Have Their Final Say on This Ill-Conceived Transaction Broadwood Partners, L.P. and its affiliates ("Broadwood" or "we"), which together own 30.2% of the outstanding common stock of
10mo agoALC STAAAlcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of StockholdersBusiness WireSTAAR Special Meeting of Stockholders Adjourned to January 6, 2026 STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the Implantable Collamer® Lens (ICL) today announced that Alcon (SIX/NYSE:ALC) has
10mo agoSTAA ALCDefender Capital Reiterates Intention to Vote AGAINST STAAR Surgical's Proposed Sale to Alcon Inc.PR NewswireDefender Capital ("Defender" or "we"), a long-term shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA) owning...
10mo agoALC STAABroadwood Partners Issues Open Letter to STAAR Surgical Board Pledging Cooperation and Support When Vote on Alcon Transaction FailsBusiness WireExpresses Confidence in STAAR's Future and the Opportunity for Significant Value Creation Believes STAAR is Worth at Least $50 Per Share If the Company Is Run in Best Interest of Shareholders Broadwood Partners, L.P.
10mo agoALC STAASTAAR Stockholders Have a Choice: Vote FOR Alcon's Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder ValueBusiness WireBroadwood Has Consistently Misled STAAR Stockholders About Takeover Interest in STAAR In Order to Derail the Alcon Merger STAAR Urges Stockholders to Vote "FOR" the Alcon Transaction on WHITE Proxy Card TODAY STAAR
11mo agoALC STAAYunqi Capital Comments on Proxy Advisors' Updated Recommendations, Urges Shareholders to Continue to Back the Company's Standalone TrajectoryBusiness WireYunqi Capital Limited (together with its affiliates and the funds it advises, "Yunqi Capital"), an investment management firm and 5.1% shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA),
11mo agoALC STAAIndependent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon TransactionBusiness WireIncreased Alcon Merger Price of $30.75 per Share is an Attractive Outcome for STAAR Stockholders STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer®
11mo agoALC STAABroadwood Partners Comments on ISS Report on Proposed Sale of STAAR Surgical to AlconBusiness WireISS Says It Would Not Be "Unreasonable for a Shareholder to Remain Opposed" to the Deal Broadwood Encourages Shareholders to Follow the Recommendations of Proxy Advisory Firms Glass Lewis and Egan-Jones, Both of Whom
11mo agoALC STAALeading Independent Proxy Advisory Firm ISS Recommends STAAR Stockholders Vote "FOR" Alcon MergerBusiness WireSTAAR Urges Stockholders to Vote "FOR" Alcon Merger on the WHITE Proxy Card TODAY STAAR Surgical Company (NASDAQ:STAA) ("STAAR"), the global leader in phakic IOLs with the EVO family of Implantable Collamer®
11mo agoALC STAABroadwood Partners: Leading Proxy Advisory Firm Glass Lewis Reaffirms Recommendation "AGAINST" STAAR Surgical Sale to AlconBusiness WireContends STAAR's Process Was Ineffective in Establishing Competitive Auction and Securing Maximum Value for Shareholders Argues Board's Procedural Credibility Is "Remarkably Threadbare" Broadwood Continues to Urge
11mo agoALC STAASTAAR Surgical Sets the Record Straight Regarding its Robust Go-Shop ProcessBusiness WireActivist Investors Have Twisted Facts Regarding STAAR's Engagement with a Potentially Interested Party During Go-Shop Process The Potentially Interested Party Reached Out on Day 21 of 30-Day Go-Shop Process and Refused
11mo agoALC STAABroadwood Partners Comments on STAAR Surgical Board Dissent on the Revised Sale to AlconBusiness WireEncouraged that at Least One Member of STAAR's Board Recognizes the Flaws of the Sale Process and that the Go-Shop Process was Performative Questions Completeness of Disclosures Given Critical Omission of Inbound
11mo agoALC STAAYunqi Capital Comments on STAAR Surgical's Go-Shop Process and Alcon's Revised OfferBusiness WireBelieves STAAR's Sale Process Was Structured to Seal the Alcon Deal, Not to Maximize Value for Shareholders The Company Is Not Ripe for Sale at This Time Continues to Urge STAAR Shareholders to Vote "AGAINST" the
11mo agoALC STAABroadwood Partners Responds to Alcon's Increase to Proposed Acquisition Price of STAAR SurgicalBusiness WireNotes That Price Bump Is Further Evidence That the Original Sale Process Was Horribly Flawed and Failed to Maximize Shareholder Value New Price Is Approximately Half the Price Offered by Alcon Twice in 2024; STAAR's
11mo agoALC STAAAlcon Announces Amended Merger Agreement with STAAR SurgicalBusiness WireAgreement follows discussions with STAAR stockholders and the closure of STAAR's "go-shop" period New terms include an increase in acquisition price and reductions in payments to executives Alcon urges STAAR
11mo agoALC STAABroadwood Partners Reiterates Opposition to STAAR Surgical's Sale to Alcon Following Conclusion of Performative Go-Shop ProcessBusiness WireBelieves Belated Go-Shop Process Fails to Cure Fundamental Flaws in the Transaction's Process, Timing, and Price Expresses Disappointment that the Self-Interested and Conflicted Board Members Continue to Press Forward
11mo agoALC STAABroadwood Partners: Proxy Advisory Firm Egan-Jones Reaffirms Its Recommendation STAAR Surgical Shareholders Vote "AGAINST" Sale to AlconBusiness WireEgan-Jones Takes No Comfort From Perfunctory Go-Shop Process and Says Concerns Regarding Objectivity and Fairness Remain the Same Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today announced
11mo agoALC STAASTAAR Surgical Announces Expiration of Go-Shop PeriodBusiness WireNo Competing Acquisition Proposals Received Results of Go-Shop Process Validate the Effectiveness of the STAAR Board's Process Now is the Right Time to Sell the Business and Alcon is the Right Buyer STAAR Surgical
11mo agoALC STAABroadwood Partners Working to Call Special Meeting of STAAR Surgical Shareholders to Remove Three DirectorsBusiness WirePursuing Board Changes to Restore Investor Confidence and Ensure Integrity of Ongoing Sale Process Broadwood Seeks to Remove the Directors Most Responsible for the Flawed Sale Process: Board Chair Elizabeth Yeu, CEO
1y agoALC STAABroadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop ProcessBusiness WireBelieves New, Independent, and Experienced Directors Are Needed in Order to Restore Trust in the Board and Confidence in the Go-Shop Process Notes Recently Appended Go-Shop Is Not a Good Substitute for a Full
1y agoALC STAASTAAR Surgical Announces Amendments to Alcon Merger AgreementBusiness Wire30-Day Go-Shop Period to Actively Solicit Other Third-Party Proposals No Termination Fee Payable to Alcon if STAAR Terminates Merger Agreement to Accept a Superior Proposal from a Qualified Bidder Alcon Waives All